Bavarian Nordic Awarded Contract from the U.S. Government to Advance the Development of new MVA-BN® based vaccines
(Thomson Reuters ONE) -
KVISTGAARD, Denmark, June 18, 2012 - Bavarian Nordic A/S (OMX: BAVA) today
announced that it has received a contract from the National Institute of Allergy
and Infectious Diseases (NIAID), part of the National Institutes of Health,
valued up to USD 17.9 million over five years. This new contract will support
the advanced development of candidate vaccine components and technologies that
accelerate the immune response for use in post-event settings following the
intentional release of pathogens that are considered a threat to public health.
Under the contract, Bavarian Nordic will evaluate several novel technologies to
accelerate and/or enhance the immune response to a combined smallpox and Marburg
virus vaccine based on MVA-BN®. Although both diseases are considered priority
pathogens by the US government, if successful, the new technologies would have
benefits for all MVA-BN®-based vaccines for infectious disease and cancer. Under
the 2 year base period of the contract, valued at USD 4.4 million, Bavarian
Nordic would evaluate several candidate vaccines in preclinical studies. This
may be followed by GMP production and a Phase I clinical trial for the lead
candidate that will be performed under several contract options that may be
exercised until the end of the contract in 2017.
The contract does not affect the company's expectations for the 2012 full year
results.
Anders Hedegaard, President & CEO commented: "This is the first major award the
company has received for a recombinant MVA-BN® based vaccine and is a
recognition of the huge potential of MVA-BN® as a vaccine vector for infectious
diseases and cancer. This contract broadens our collaboration with the US
Government and we are excited to explore the opportunity to expand the scope of
application for our MVA-BN® technology platform, which we have successfully
developed through our contracts with the U.S. Government to develop our
IMVAMUNE® smallpox vaccine."
Asger Aamund
Chairman of the Board
Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline targets cancer
and infectious diseases, and includes ten development programs. In oncology, the
company's lead program is PROSTVAC®, a therapeutic vaccine candidate for
advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial
and is being developed under a collaboration agreement with the National Cancer
Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC® has been tested in
nearly 600 patients. In infectious diseases, the company's lead program is
IMVAMUNE®, a third-generation smallpox vaccine candidate that is being developed
and supplied for emergency use to the U.S. Strategic National Stockpile under a
contract with the U.S. Government. For more information, visit www.bavarian-
nordic.com
Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.
201208uk:
http://hugin.info/100065/R/1619947/517553.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bavarian Nordic A/S via Thomson Reuters ONE
[HUG#1619947]
Unternehmensinformation / Kurzprofil:
Datum: 18.06.2012 - 08:01 Uhr
Sprache: Deutsch
News-ID 157333
Anzahl Zeichen: 4690
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 194 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic Awarded Contract from the U.S. Government to Advance the Development of new MVA-BN® based vaccines"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
